Zinzino: ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2024
Zinzino group revenue increased with a total of 25 %, compared with the previous year.
The revenue in February for Zinzino's sales markets increased by 27 % and amounted to SEK 138.7 (109.6) million. Faun Pharma's external sales increased by 11 % and amounted to SEK 9.7 (8.7) million. Overall, the Group increased revenues by 25 % to SEK 148.4 (118.3) million compared with the previous year.
Accumulated revenue for January - February 2024 increased by 20 % to SEK 297.4 (247.8) million.
Revenues were distributed as follows:
Regions,MSEK 24 23 Change YTD 2024 YTD 2023 Change
-Feb -Feb
The Nordics 22.2 23.2 -4% 45.1 46.8 -4%
Central 36.7 26.9 36% 77.6 55.4 40%
Europe
East Europe 29.9 25.2 19% 61.7 58,0 6%
South & West 24.6 14.4 71% 46.6 30.3 54%
Europe
The Baltics 8.3 6.1 36% 16.3 13.4 22%
North 12.2 6.3 94% 22.5 12.6 79%
America
Asia-Pacific 3.6 6.5 -45% 7.6 11.1 -32%
Africa 1.2 1,0 2.2 2.4 -8%
20%
Zinzino 109.6 27% 279.6 230.0 22%
138.7
Faun Pharma 9.7 8.7 11% 17.8 17.8 0%
Zinzino 148.4 118.3 25% 297.4 247.8 20%
Group
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge: marketing@zinzino.com
Certified Adviser: Carnegie Investment Bank AB (publ)